These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
431 related articles for article (PubMed ID: 33463454)
21. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors and underlying mechanisms. Kashihara N; Kidokoro K; Kanda E Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):112-118. PubMed ID: 31725011 [TBL] [Abstract][Full Text] [Related]
22. Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind, placebo-controlled exploratory trial. Antlanger M; Domenig O; Kaltenecker CC; Kovarik JJ; Rathkolb V; Müller MM; Schwaiger E; Hecking M; Poglitsch M; Säemann MD; Kopecky C Diabetes Obes Metab; 2022 May; 24(5):816-826. PubMed ID: 34984822 [TBL] [Abstract][Full Text] [Related]
23. The residual cardiorenal risk in type 2 diabetes. Giugliano D; Maiorino MI; Bellastella G; Esposito K Cardiovasc Diabetol; 2021 Feb; 20(1):36. PubMed ID: 33546683 [TBL] [Abstract][Full Text] [Related]
24. Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results. Weir MR; McCullough PA; Buse JB; Anderson J Am J Nephrol; 2020; 51(4):276-288. PubMed ID: 32172239 [TBL] [Abstract][Full Text] [Related]
26. Sodium-Glucose Cotransporter-2 Inhibitors-Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials. Gohda T; Murakoshi M Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430228 [TBL] [Abstract][Full Text] [Related]
27. Sodium-glucose co-transporter-2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis. Giugliano D; Longo M; Caruso P; Maiorino MI; Bellastella G; Esposito K Diabetes Obes Metab; 2021 Jul; 23(7):1672-1676. PubMed ID: 33710721 [TBL] [Abstract][Full Text] [Related]
28. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. Zou H; Zhou B; Xu G Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711 [TBL] [Abstract][Full Text] [Related]
29. Novel therapeutic agents for the treatment of diabetic kidney disease. Hartman RE; Rao PSS; Churchwell MD; Lewis SJ Expert Opin Investig Drugs; 2020 Nov; 29(11):1277-1293. PubMed ID: 32799584 [TBL] [Abstract][Full Text] [Related]
33. Pleiotropic effects of antidiabetic agents on renal and cardiovascular outcomes: a meta-analysis of randomized controlled trials. Chewcharat A; Takkavatakarn K; Isaranuwatchai S; Katavetin P; Praditpornsilpa K; Eiam-Ong S; Susantitaphong P Int Urol Nephrol; 2020 Sep; 52(9):1733-1745. PubMed ID: 32524495 [TBL] [Abstract][Full Text] [Related]
34. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes. Woo V; Connelly K; Lin P; McFarlane P Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677 [No Abstract] [Full Text] [Related]
36. Chronic kidney disease in type 2 diabetes: Implications for managing glycaemic control, cardiovascular and renal risk. Stephens JW; Brown KE; Min T Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():32-45. PubMed ID: 32267078 [TBL] [Abstract][Full Text] [Related]
37. Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists. Prattichizzo F; de Candia P; Ceriello A Metabolism; 2021 Jul; 120():154799. PubMed ID: 34029597 [TBL] [Abstract][Full Text] [Related]
38. SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects. Garofalo C; Borrelli S; Liberti ME; Andreucci M; Conte G; Minutolo R; Provenzano M; De Nicola L Medicina (Kaunas); 2019 Jun; 55(6):. PubMed ID: 31212638 [TBL] [Abstract][Full Text] [Related]
39. Do effects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease? Rajasekeran H; Cherney DZ; Lovshin JA Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):358-367. PubMed ID: 28582367 [TBL] [Abstract][Full Text] [Related]
40. New Glucose-Lowering Agents for Diabetic Kidney Disease. de Vos LC; Hettige TS; Cooper ME Adv Chronic Kidney Dis; 2018 Mar; 25(2):149-157. PubMed ID: 29580579 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]